Andres Darquea, MD
Endocrinology, Diabetes & Metabolism · Roswell, NMNPI 1891215679
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Myriad Women's Health, Inc. at 34.9% of the total. Reporting peaked in 2023 at $578 and has fallen 66.2% since, to $196 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NM, where the typical reported total is $1,943.
Across 33 payments — averaging $28.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Women's Health, Inc.$331
- Novartis$137
- AstraZeneca$98
- Merck$84
- Sobi, Inc$55
- Abbott$47
- plus $197 from 10 others
What the payments were for
- Food & beverage$93298%
- Education$162%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Women's Health, Inc. | 1 | $331 |
| Novartis | 6 | $137 |
| AstraZeneca(2 entities) | 5 | $98 |
| Merck | 5 | $84 |
| Sobi, Inc | 3 | $55 |
| Abbott | 2 | $47 |
| Inspire Medical Systems, Inc. | 1 | $35 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Insulet Corporation | 1 | $22 |
| Karyopharm Therapeutics Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Axonics, Inc. | 1 | $15 |
| Coherus Oncology, Inc. | 1 | $15 |
| Tersera Therapeutics LLC | 1 | $14 |
| Spectrum Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myRisk$331
How this compares
$948 in reported general payments places this provider in the 40th percentile of 42 endocrinology, diabetes & metabolism providers in New Mexico.
See all endocrinology, diabetes & metabolism providers in New Mexico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 560 | $474,393 |
| TrulicityDulaglutide | 389 | $464,237 |
| OzempicSemaglutide | 343 | $379,828 |
| SomavertPegvisomant | 12 | $128,563 |
| MounjaroTirzepatide | 81 | $105,989 |
| RybelsusSemaglutide | 40 | $60,762 |
| FarxigaDapagliflozin Propanediol | 63 | $56,995 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 51 | $53,572 |
| Humulin R U-500Insulin Regular, Human | 23 | $52,451 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 55 | $51,116 |
| JanuviaSitagliptin Phosphate | 51 | $44,975 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 113 | $42,665 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 69 | $41,734 |
| Humalog Kwikpen U-200Insulin Lispro | 25 | $40,194 |
| Humalog Kwikpen U-100Insulin Lispro | 157 | $39,565 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $16 | $458,621429 claims |
| MerckJanuvia, Janumet, Steglatro | $84 | $67,45684 claims |
| AstraZenecaFarxiga | $98 | $56,99563 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 42 endocrinology, diabetes & metabolism providers in New Mexico.
Other endocrinology, diabetes & metabolism in Roswell
- Mose JulyRoswell$117
- Robert FerraroAlbuquerque$101K
- Rina Patel TrujilloAlbuquerque$100K
- Jeremy GleesonAlbuquerque$46K
- David SchadeAlbuquerque$16K
- Mansi MehtaAlbuquerque$15K
- Matthew BouchonvilleAlbuquerque$7K
- Teodor DuroAlbuquerque$6K
- Andrew LancasterAlamogordo$6K
- Ivan PinonAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.